JP2010539893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539893A5 JP2010539893A5 JP2010525273A JP2010525273A JP2010539893A5 JP 2010539893 A5 JP2010539893 A5 JP 2010539893A5 JP 2010525273 A JP2010525273 A JP 2010525273A JP 2010525273 A JP2010525273 A JP 2010525273A JP 2010539893 A5 JP2010539893 A5 JP 2010539893A5
- Authority
- JP
- Japan
- Prior art keywords
- stretch
- nucleic acid
- acid according
- nucleotides
- box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 68
- 108020004707 nucleic acids Proteins 0.000 claims 63
- 102000039446 nucleic acids Human genes 0.000 claims 63
- 239000002773 nucleotide Substances 0.000 claims 40
- 125000003729 nucleotide group Chemical group 0.000 claims 39
- 239000000523 sample Substances 0.000 claims 13
- 102000000989 Complement System Proteins Human genes 0.000 claims 12
- 108010069112 Complement System Proteins Proteins 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 9
- 210000000056 organ Anatomy 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 210000004351 coronary vessel Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000003414 extremity Anatomy 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010001053 acute respiratory failure Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000005993 intestine dysfunction Effects 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07018750.5 | 2007-09-24 | ||
| EP07018750 | 2007-09-24 | ||
| PCT/EP2008/008097 WO2009040113A2 (en) | 2007-09-24 | 2008-09-24 | C5a BINDING NUCLEIC ACIDS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539893A JP2010539893A (ja) | 2010-12-24 |
| JP2010539893A5 true JP2010539893A5 (cg-RX-API-DMAC7.html) | 2011-11-04 |
| JP5798320B2 JP5798320B2 (ja) | 2015-10-21 |
Family
ID=40174751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010525273A Expired - Fee Related JP5798320B2 (ja) | 2007-09-24 | 2008-09-24 | Ｃ５ａに結合する核酸 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8507456B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2562256A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5798320B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100072185A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101809154A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008303775A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0817260A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2700441A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010003109A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2010116245A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009040113A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8066757B2 (en) | 2007-10-17 | 2011-11-29 | Mindframe, Inc. | Blood flow restoration and thrombus management methods |
| US20120065254A1 (en) * | 2009-03-23 | 2012-03-15 | Noxxon Pharma Ag | C5A binding nucleic acids and the use thereof |
| EP2480888B1 (en) * | 2009-09-25 | 2016-11-30 | XOMA Technology Ltd. | Screening methods |
| JP2014514329A (ja) * | 2011-04-26 | 2014-06-19 | リガド・バイオサイエンシーズ・インコーポレーテツド | Ｐｅｇ化オリゴヌクレオチドの製造方法 |
| CN103582887B (zh) * | 2011-06-07 | 2017-07-04 | 皇家飞利浦有限公司 | 提供核苷酸序列数据的方法和测序装置 |
| WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| PT2802660T (pt) | 2012-01-10 | 2020-04-21 | Aptarion Biotech Ag | Novos ácidos nucleicos que se ligam a c5a |
| WO2015066027A2 (en) | 2013-10-28 | 2015-05-07 | Dots Devices, Inc. | Allergen detection |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CN106860867A (zh) * | 2017-02-23 | 2017-06-20 | 中山大学 | 己糖激酶2特异性抑制剂在急性中枢神经系统损伤疾病中的应用 |
| EP3553521A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Gingivitis diagnostic methods, uses and kits |
| WO2025196240A1 (en) | 2024-03-20 | 2025-09-25 | Aptarion Biotech Ag | Method of treating a disorder with a c5a inhibitor |
| EP4620474A1 (en) | 2024-03-20 | 2025-09-24 | APTARION biotech AG | Method of treating a disorder with a c5a inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395888B1 (en) * | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| EP2138575B8 (en) | 2002-02-20 | 2013-07-24 | Mersana Therapeutics, Inc. | Conjugates comprising a biodegradable polymer and uses therefor |
| FI20051017A7 (fi) | 2003-04-13 | 2005-11-28 | Enzon Pharmaceutivals Inc | Polymeeriset oligonukleotidiaihiolääkkeet |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US20070116710A1 (en) * | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| EP1713509A2 (de) | 2004-02-09 | 2006-10-25 | Noxxon Pharma AG | Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden |
| US7803931B2 (en) * | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP2578683B9 (en) * | 2004-02-12 | 2015-04-15 | Archemix LLC | Aptamer therapeutics useful in the treatment of complement-related disorders |
| AU2005232371B2 (en) | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
| CN104623692A (zh) * | 2006-03-08 | 2015-05-20 | 阿切埃米克斯股份有限公司 | 治疗视觉失调中使用的补体结合适体和抗-c5药物 |
| EP2063709A2 (en) | 2006-09-15 | 2009-06-03 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| EP2061901A2 (en) | 2006-10-31 | 2009-05-27 | Noxxon Pharma AG | Methods for detection of a single- or double-stranded nucleic acid molecule |
| US20120065254A1 (en) * | 2009-03-23 | 2012-03-15 | Noxxon Pharma Ag | C5A binding nucleic acids and the use thereof |
-
2008
- 2008-09-24 AU AU2008303775A patent/AU2008303775A1/en not_active Abandoned
- 2008-09-24 JP JP2010525273A patent/JP5798320B2/ja not_active Expired - Fee Related
- 2008-09-24 US US12/679,307 patent/US8507456B2/en not_active Expired - Fee Related
- 2008-09-24 BR BRPI0817260-9A2A patent/BRPI0817260A2/pt not_active IP Right Cessation
- 2008-09-24 RU RU2010116245/10A patent/RU2010116245A/ru not_active Application Discontinuation
- 2008-09-24 CN CN200880108439A patent/CN101809154A/zh active Pending
- 2008-09-24 EP EP12006735.0A patent/EP2562256A3/en not_active Withdrawn
- 2008-09-24 MX MX2010003109A patent/MX2010003109A/es not_active Application Discontinuation
- 2008-09-24 CA CA2700441A patent/CA2700441A1/en not_active Abandoned
- 2008-09-24 WO PCT/EP2008/008097 patent/WO2009040113A2/en not_active Ceased
- 2008-09-24 EP EP08834443A patent/EP2205734A2/en not_active Withdrawn
- 2008-09-24 KR KR1020107005454A patent/KR20100072185A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539893A5 (cg-RX-API-DMAC7.html) | ||
| RU2010116245A (ru) | НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a | |
| US11090303B2 (en) | Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders | |
| Hayashida et al. | Exogenous mitochondrial transplantation improves survival and neurological outcomes after resuscitation from cardiac arrest | |
| AU2007299043B2 (en) | Expansion method for adult stem cells from blood, particularly peripheral blood, and relative application in medical field | |
| TW201134482A (en) | Aptamers to β -NGF and their use in treating β -NGF mediated diseases and disorders | |
| JP2015509705A5 (cg-RX-API-DMAC7.html) | ||
| JP6640725B2 (ja) | ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す | |
| US20230330271A1 (en) | Thrombus imaging aptamers and methods of using same | |
| US9603831B2 (en) | Artemisinin and its derivatives for use in the treatment of kidney disease | |
| Põldoja | Structure and blood supply of the superior part of the shoulder joint capsule | |
| CN103805563B (zh) | 一种脑靶向干细胞及其制备方法和应用 | |
| CN118772296B (zh) | 一种多肽药物及其在预防或治疗腹主动脉瘤中的应用 | |
| WO2017147044A1 (en) | Peptides and methods for treatment of neurodegenerative diseases | |
| CN106562944A (zh) | Fty720在制备预防或治疗缺血性脑卒中的药物中的应用 | |
| ES2546094T3 (es) | Antagonistas contra la interacción de PF4 y RANTES | |
| Kar et al. | Anesthesia management of renal transplantation: an update | |
| US20240398792A1 (en) | Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease | |
| Tran et al. | Shamanic Kambô Frog Hyponatremic Toxicity Leading to Brain Death: A Case Report | |
| Li et al. | Targeted vancomycin delivery via in situ albumin conjugation and acid-triggered drug release for reduced nephrotoxicity | |
| US20250177479A1 (en) | Depsipeptide-based amphiphilic buliding block to inhibit protein-protein interactions, nanostructure comprised thereof and uses thereof | |
| Bozan et al. | The diagnostic efficacy of some ischemic markers (urotensin II and urotensin II related peptide) in early diagnosis of intestinal ischemia in experimentally increased intraabdominal pressure in rats | |
| CA3251755A1 (en) | VASCULARIZING AGENTS | |
| Shi et al. | Development of Oxytocin-and Vasopressin-Network in the Supraoptic and Paraventricular Nuclei of Fetal Sheep | |
| Poudel et al. | Endothelial Cell-Specific G2APOL1 Expression Induces Hypertension via STING and NLRP3 Pathways: SA-PO764 |